

Michele Pozzoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3579039/publications.pdf>

Version: 2024-02-01

17
papers

452
citations

840119

11
h-index

887659

17
g-index

17
all docs

17
docs citations

17
times ranked

649
citing authors

#	ARTICLE	IF	CITATIONS
1	The nasal delivery of nanoencapsulated statins – an approach for brain delivery. International Journal of Nanomedicine, 2016, Volume 11, 6575-6590.	3.3	65
2	Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opinion on Drug Delivery, 2019, 16, 453-466.	2.4	62
3	Application of RPMI 2650 nasal cell model to a 3D printed apparatus for the testing of drug deposition and permeation of nasal products. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 107, 223-233.	2.0	53
4	Opportunities and Challenges for the Nasal Administration of Nanoemulsions. Current Topics in Medicinal Chemistry, 2015, 15, 356-368.	1.0	52
5	Application of a Thermosensitive In Situ Gel of Chitosan-Based Nasal Spray Loaded with Tranexamic Acid for Localised Treatment of Nasal Wounds. AAPS PharmSciTech, 2019, 20, 299.	1.5	38
6	Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Teijin Puvlizer Rhinocort device and formulation. Drug Development and Industrial Pharmacy, 2016, 42, 1660-1668.	0.9	32
7	Development of a Soluplus budesonide freeze-dried powder for nasal drug delivery. Drug Development and Industrial Pharmacy, 2017, 43, 1510-1518.	0.9	25
8	Formulation and Characterization of Native and Crosslinked Hyaluronic Acid Microspheres for Dermal Delivery of Sodium Ascorbyl Phosphate: A Comparative Study. Pharmaceutics, 2018, 10, 254.	2.0	22
9	Nanoemulsion-Enabled Oral Delivery of Novel Anticancer ω -3 Fatty Acid Derivatives. Nanomaterials, 2018, 8, 825.	1.9	20
10	Combination of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate for the treatment of inflammatory lung diseases: An in vitro study. European Journal of Pharmaceutical Sciences, 2018, 120, 96-106.	1.9	19
11	An in vitro model for assessing drug transport in cystic fibrosis treatment: Characterisation of the CuFi-1 cell line. European Journal of Pharmaceutics and Biopharmaceutics, 2020, 156, 121-130.	2.0	15
12	Resveratrol solid lipid microparticles as dry powder formulation for nasal delivery, characterization and in vitro deposition study. Journal of Microencapsulation, 2016, 33, 735-742.	1.2	12
13	Co-Spray-Dried Urea Cross-Linked Hyaluronic Acid and Sodium Ascorbyl Phosphate as Novel Inhalable Dry Powder Formulation. Journal of Pharmaceutical Sciences, 2019, 108, 2964-2971.	1.6	11
14	In vitro characterization of physico-chemical properties, cytotoxicity, bioactivity of urea-crosslinked hyaluronic acid and sodium ascorbyl phosphate nasal powder formulation. International Journal of Pharmaceutics, 2019, 558, 341-350.	2.6	11
15	Anti-Inflammatory Properties of Statin-Loaded Biodegradable Lecithin/Chitosan Nanoparticles: A Step Toward Nose-to-Brain Treatment of Neurodegenerative Diseases. Frontiers in Pharmacology, 2021, 12, 716380.	1.6	10
16	Is there a role for inhaled anti-inflammatory drugs in cystic fibrosis treatment?. Expert Opinion on Orphan Drugs, 2018, 6, 69-84.	0.5	3
17	Tobramycin and Colistin display anti-inflammatory properties in CuFi-1 cystic fibrosis cell line. European Journal of Pharmacology, 2021, 902, 174098.	1.7	2